Living meta-analysis and evidence synthesis of therapies for COVID19  

colchicine vs. standard of care - COVID 19 hospitalized some concern in risk of bias

• inconclusive results for: 28-d mortality; 28-d composite (new requirement of mechanical ventilation or death)

meta-analysis

remdesivir vs. placebo - COVID 19 outpatients low risk of bias

• statistically conclusive 87 % decrease in Covid-19–related hospitalization or death from any cause by day 28
• suggested 72 % decrease in Hospitalization for any cause by day 28
• suggested 75 % decrease in Patients with serious adverse events
• inconclusive results for: Death from any cause by day 28; Patients with adverse event leading to discontinuation of trial regimen; Patients with any adverse event

meta-analysis

nirmatrelvir / ritonavir (Paxlovid) vs. placebo - COVID 19 outpatients NA risk of bias

• statistically conclusive 90 % decrease in Hospitalization or death from any cause in patients treated within three days of symptom onset.
• suggested 96 % decrease in Death at day 28

risk of bias not assessable

meta-analysis

lenzilumab vs. placebo - COVID-19 mild to moderate some concern in risk of bias

• statistically conclusive 35 % decrease in Death or ventilation (derived from survival without ventilation to day 28)
• inconclusive results for: Mortality

meta-analysis

convalescent plasma treatment vs. standard of care - COVID 19 hospitalized some concern in risk of bias

• inconclusive results for: All-cause mortality; Progression to ventilator treatment

meta-analysis